Phase 1 testing of HW201877 in healthy adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, placebo-controlled Phase 1 trial enrolls healthy adults to examine safety, tolerability, pharmacokinetics, pharmacodynamics, and the effect of food on HW201877. Part 1 uses single ascending doses and includes a two-period crossover cohort to measure food effect, while Part 2 uses multiple ascending doses to study repeat dosing. Subjects are randomized to HW201877 capsules or placebo and monitored with clinical labs, adverse event reporting, and serial PK/PD sampling. The trial is conducted at The First Hospital of Jilin University in Changchun, China with participants aged 18–55 and prespecified weight, BMI, and smoking criteria.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Before enrollment in the study, each subject shall sign the informed consent form and be fully apprised of the study content, implementation procedures and potential adverse reactions.
* Subjects are willing to voluntarily use effectivecontraceptives from screening to at least 6 months after the last dose administration.
* 18 years to 55 years (inclusive), male and female.
* Male subjects weight ≥50 kg and female subjects weight ≥45 kg. Bodymass index (BMI) : 18-28 kg/m2 (inclusive) .

Key Exclusion Criteria:

* Smoking more than 5 cigarettes per day within 3 months prior to screening.
* Allergic diathesis (with a history of allergies to multiple drugs and foods).
* A history of drug abuse and/or alcoholism (consuming 14 units of alcohol per week; 1 unit = 285 mL of beer, 25 mL of distilled spirits, or 100 mL of wine).
* Have taken any medications that alter hepatic enzyme activity within 28 days prior to screening.
* Have consumed special diets (including pitaya, mango, lime, grapefruit, carambola, orange, grapefruit or grapefruit-containing products, etc.) or engaged in strenuous exercise within 2 weeks prior to screening, or having other factors that may affect the absorption, distribution, metabolism and excretion of the study drug.
* Have taken any investigational drugs or participated in any other clinical drug trials within 3 months prior to the first administration of the study drug.
* Clinically significant abnormalities in clinical laboratory tests, or a history of clinically significant findings of the following diseases within 12 months prior to screening (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardio-cerebrovascular diseases).
* Unable to tolerate venipuncture, or with a history of needle phobia or hematophobia.
* Not suitable for this study as judged by the investigator.

Where it's running

• The First Hospital of Jilin University
  Changchun, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Maternal and infant microbiome links to infant gut inflammation and pregnancy outcomes in people with IBD

  This project will see if mothers' microbiomes, diets, and breastmilk are linked to infant gut inflammation (measured by fecal calprotectin) in pregnant people with and without IBD.

  Recruiting University of British Columbia · Vancouver, British Columbia and 1 other locations · NCT07385807

• Infliximab plus the Crohn's Disease Exclusion Diet for children with Crohn's disease

  This will test whether starting a Crohn's Disease Exclusion Diet at the same time as infliximab helps children with moderate-to-severe Crohn's disease get better and stay in remission.

  Recruiting University of British Columbia · Vancouver, British Columbia · NCT07314606

• SMART-IBD app for teens with inflammatory bowel disease

  This will test whether the SMART-IBD smartphone app helps adolescents ages 13–17 with IBD take their medicines and manage symptoms better than completing daily diaries alone.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07195123

• Melatonin to improve sleep quality in adults with inflammatory bowel disease in remission

  This study tests whether melatonin can improve sleep quality in adults with IBD who are in clinical remission.

  Recruiting Phase 4 Mahidol University · Bangkok Noi, Bangkok · NCT07737665

• Individualizing Anti-TNF Therapy in IBD

  This study tests whether genetic markers can predict which anti-TNF–naïve IBD patients will respond to their first anti-TNF treatment.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT07644117

• BDHK-2009 safety test in healthy adults

  This early-stage test checks if BDHK-2009 tablets are safe and tolerable in healthy adults aged 18–55 compared with placebo.

  Recruiting Phase 1 Benethera (Shaoxing) Biotechnology Co., Ltd. · Hangzhou, Zhejiang · NCT07632573

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.